|Bid||0.0720 x 0|
|Ask||0.0730 x 0|
|Day's Range||0.0650 - 0.0730|
|52 Week Range||0.0170 - 0.0940|
|Beta (3Y Monthly)||-3.88|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 1, 2016 - Mar 5, 2016|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
MELBOURNE, Australia, Sept. 17, 2019 /PRNewswire/ -- Antisense Therapeutics ("ANP" or the "Company") is pleased to advise that a review of the preliminary data from the 6 patients who have completed their 24 weeks of dosing in the Phase II clinical trial of ANP's immunomodulatory therapy, ATL1102 for Duchenne Muscular Dystrophy (DMD) therapy, is indicative of a positive drug effect of ATL1102 at the dose tested both at an immunomodulatory (i.e.
Anyone researching Antisense Therapeutics Limited (ASX:ANP) might want to consider the historical volatility of the...
Mark Diamond became the CEO of Antisense Therapeutics Limited (ASX:ANP) in 2001. This report will, first, examine the...
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! If you own shares in Antisense Therapeutics Limited (ASX:ANP) thenRead More...
Mark Diamond has been the CEO of Antisense Therapeutics Limited (ASX:ANP) since 2001. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, Read More...
Every investor in Antisense Therapeutics Limited (ASX:ANP) should be aware of the most powerful shareholder groups. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often Read More...